Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Long COVID
NCT07128082Phase 2Active, not recruiting
- Sponsor
- Scripps Research
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Placebo with Tirzepatide (2 arms). Primary endpoint: Fatigue Severity Scale at 12 months. Started Oct 2025; status: active, not recruiting.
02
Drugs
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT07128082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128082.